山玫胶囊治疗慢性脑供血不足属气滞血瘀证的临床观察 - 中国药房.pdf

山玫胶囊治疗慢性脑供血不足属气滞血瘀证的临床观察 1＊ 2# 2 刘 珠 ，高振强 ，刘俊艳 （1.石家庄市食品药品检验所，石家庄 050031；2.河北医科大学第三医院，石家庄 050051） 中图分类号 R743 文献标志码 A 文章编号 1001-0408（2013）36-3408-03 DOI 10.6039/j.issn. 1001-0408.2013.36.16 摘 要 目的：观察山玫胶囊治疗慢性脑供血不足属气滞血瘀证的疗效和安全性。方法：将211例患者按照3∶1的比例随机分为 两组，试验组159例、对照组52例，其中试验组153例、对照组50例符合方案集，纳入分析。试验组患者口服山玫胶囊每次0.75g ， tid ；对照组患者口服心脑康胶囊每次1g ，tid 。两组疗程均为4周。治疗结束后评价两组的疗效和安全性。结果：试验组与对照组 的症状疗效总有效率分别为84.96％和74.00％，两组比较差异无统计学意义（P ＞0.05）；中医证候疗效总有效率分别为83.00％和 76.00％，两组比较差异无统计学意义（P ＞0.05）。两组患者治疗前后甘油三酯、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆 固醇等指标变化组间比较，差异无统计学意义（P ＞0.05）。两组患者不良反应发生率的差异无统计学意义（P ＞0.05）。结论：山玫 胶囊治疗慢性脑供血不足属气滞血瘀证疗效确切，安全性较好，与心脑康胶囊相仿。 关键词 山玫胶囊；慢性脑供血不足；气滞血瘀证；疗效；安全性 Clinical Observation of Shanmei Capsules in the Treatment of Chronic Cerebral Circulation Insufficiency Complicating with Qi-stagnancy and Blood Stasis Syndrome 1 2 2 LIU Zhu ，GAO Zhen-qiang ，LIU Jun-yan （1.Shijiazhuang Institute for Food and Drug Control ，Shijiazhuang 050031，China ；2.The Third Hospital of Hebei Medical University ，Shijiazhuang 050051，China ） ABSTRACT OBJECTIVE ：To observe therapeutic efficacy and safety of Shanmei capsules in the treatment of chronic cerebral in- sufficiency with qi-stagnancy and blood stasis. METHODS ：211 patients were randomly divided into 2 groups in accordance with the ratio of 3∶1，i.e. 159cases in trial group and 52 cases in control group ，among which 153cases of trial group and 50 cases of control group were in line with scheme volume and included in study. Trial group orally received Shanmei capsules 0.75 g ，3times a day ；control group was given Xinnaokang capsule 1g ，3times a day for 4 weeks. After the treatment ，clinical efficacy and safe- ty of 2 groups were evaluated. RESULTS ：The total effective rates of trial group and control group were 84.96％and 74.00％； there was no statistical significance